Clinical Trial Update: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ruxolitinib for T-cell large granular lymphocytic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Large Granular Lymphocytic Leukemia

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Jonathan Brammer | Conditions: T-Cell Large Granular Lymphocyte Leukemia | Phase 2 | Status: RECRUITING